home / stock / mnpr / mnpr message board
Subject | By | Source | When |
---|---|---|---|
$1.40 Not nice. | willlbone | investorshub | 03/28/2023 3:52:30 PM |
$4+ nice | wesley_ | investorshub | 11/08/2022 9:35:40 PM |
Monopar Announces Completion of Phase 2b Enrollment and | subslover | investorshub | 10/05/2022 1:28:03 PM |
Well not looking great at present. However | Condors rugby | investorshub | 02/23/2021 2:47:53 PM |
With a price target of 49 and extremely | Condors rugby | investorshub | 02/12/2021 4:46:27 PM |
but f---ing low flot dont you think | all right all right | investorshub | 02/11/2021 4:28:40 PM |
Very active trading on low float. Looks | Condors rugby | investorshub | 02/11/2021 3:10:57 PM |
taking a position at 13.86 low float. lets go | makingitnow | investorshub | 01/28/2021 1:26:58 PM |
Monopar Therapeutics shares are trading higher after Roth | crudeoil24 | investorshub | 01/28/2021 12:51:16 PM |
Monopar Therapeutics Inc. is a clinical stage biopharmaceutical | crudeoil24 | investorshub | 01/28/2021 12:50:30 PM |
News, Short Squeeze, Breakout and More Instantly...
Monopar Therapeutics Inc. Company Name:
MNPR Stock Symbol:
NASDAQ Market:
WILMETTE, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its abstract on the preclinical data for its radiopharmaceutical program MN...
WILMETTE, Ill., April 16, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused o...
WILMETTE, Ill., April 16, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that it has filed a provisional patent application pertaining to the recent adva...